Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-28T02:36:02.807Z Has data issue: false hasContentIssue false
  • English
  • Français

Professional attitudes in the UK towards neuroleptic maintenance therapy in schizophrenia

The problem of inadequate prophylaxis

Published online by Cambridge University Press:  02 January 2018

D. A. W. Johnson  and
J. G. C. Rasmussen
D. A. W. Johnson
Affiliation:
South Manchester University Hospitals (NHS) Trust c/o 14 St John's Street Manchester M3 4DZ
J. G. C. Rasmussen*
Affiliation:
Leacroft, Ifield Road, West Green, Crawley, West Sussex RH11 7BS
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Controlled trials show that about 80% of schizophrenic patients remain relapse free when given adequate neuroleptic maintenance therapy but this level of efficacy is not achieved in clinical practice. Guidelines for proper use of neuroleptics in relapse prevention were developed by a group of experienced psychiatrists – the ‘Consensus Group’ – in 1989. In this survey, the views of UK psychiatrists, GPs, CPNs and pharmacists involved in community care of schizophrenia were compared with the Guidelines.

Type
Original Papers
Information
Psychiatric Bulletin , Volume 21 , Issue 7 , July 1997 , pp. 394 - 397
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1997 The Royal College of Psychiatrists

References

Blom-Cooper, L., Murphy, E. & Hally, H. (1993) The Falling Shadow. One Patients Mental Health Care, 1978–1993. Report of the Committee of Enquiry into the Events Leading up to, and Surrounding, the Fatal Incident at the Edith Morgan Centre, Torbay, 1st September, 1993. London: Duckworth.Google Scholar
BMJ News (1995) Mental health law obsolete, says inquiry. British Medical Journal, 310, 145–146.CrossRefGoogle Scholar
Boyd, W., Sims, A. & Brooker, A. (1994) A Preliminary Report on Homicide. Steering Committee of the Confidential Inquiry into Homicides & Suicides by Mentally Ill People.Google Scholar
Crow, T. J., McMillam, J. P., Johnson, A. L., et al (1986) The Northwick Park study of first episodes of schizophrenia: II. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120–127.CrossRefGoogle Scholar
Davis, J. M., Metalon, L., Watanabe, M. D., et al (1994) Depot antipsychotic drugs: Place in therapy. Drugs, 47, 741–773.CrossRefGoogle ScholarPubMed
Goad, T. D., & Ezell, T. R. (1990) Drug use evaluation programs for psychotropic medications. American Journal of Hospital Pharmacy, 47, 132–136.Google ScholarPubMed
Hale, A. (1993) Will the new antipsychotics improve the treatment of schizophrenia? Depot preparations still hold the key to compliance. British Medical Journal, 307, 249–250.CrossRefGoogle Scholar
Johnson, D. A. W. (1976) The expectation of outcome for maintenance therapy in schizophrenia. British Journal of Psychiatry, 128, 246–250.CrossRefGoogle Scholar
Johnson, D. A. W. (1979) Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. British Journal of Psychiatry, 135, 524–530.CrossRefGoogle ScholarPubMed
Johnson, D. A. W. & Wright, W. (1990) Drug prescribing to schizophrenic outpatients on depot injections: Repeat surveys over 18 years. British Journal of Psychiatry, 156, 822–834.CrossRefGoogle ScholarPubMed
Kissling, W. (1992) Ideal and reality of neuroleptic relapse prevention. British Journal of Psychiatry, 161 (suppl. 18). 133–139.CrossRefGoogle Scholar
Kissling, W., Kane, J. M., Barnes, S. J., et al (1991) Guidelines for neuroleptic relapse prevention in schizophrenia: Towards a consensus view. In Schizophrenia (ed. Kissling, W. W.), pp. 155–163. Berlin: Springer-Verlag.Google Scholar
Putten, T. Van, Morden, S. P. & Wissheng, W. C. (1990) Surreptitious non-compliance with oral fluphenazine in a voluntary inpatient population. Archives of General Psychiatry, 47, 786–787.CrossRefGoogle Scholar
Tylee, A. (1995) Drug treatment for schizophrenia. The Practitioner, 239, 116–119.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.